Clinical Trial Update: Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

View source ↗

Summary

This clinical trial update notes that the study evaluating pharmacogenetic predictors of toxicity in pre-menopausal women with early breast cancer treated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Breast Cancer | Status: TERMINATED